Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Shionogi & Co., Ltd. Unsponsored ADR (SGIOY : OTC)
 
 • Company Description   
Shionogi & Co., Ltd. engages in the research, development, manufacture and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Its primary products Tivicay for HIV treatment; Mulpleta for the treatment of thrombocytopenia; Xofluza, an influenza drug; Symproic for opioid-induced constipation treatment and Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment. Shionogi & Co., Ltd. is based in Osaka, Japan.

Number of Employees: 4,959

 
 • Price / Volume Information   
Yesterday's Closing Price: $8.95 Daily Weekly Monthly
20 Day Moving Average: 71,257 shares
Shares Outstanding: 1,701.38 (millions)
Market Capitalization: $15,227.34 (millions)
Beta: 0.20
52 Week High: $9.14
52 Week Low: $6.53
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 0.56% -1.21%
12 Week 4.43% -5.14%
Year To Date 28.59% 16.10%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1-8 DOSHOMACHI 3-CHOME
-
OSAKA,M0 541-0045
JPN
ph: 816-620-2216
fax: -
None http://www.shionogi.com
 
 • General Corporate Information   
Officers
IsaoTeshirogi - President and CEO
Keiichi Ando - Chairperson
Takuko Sawada - Director and Vice Chairperson of the Board
Hiroshi Ozaki - Director
Fumi Takatsuki - Director

Peer Information
Shionogi & Co., Ltd. Unsponsored ADR (GSAC)
Shionogi & Co., Ltd. Unsponsored ADR (CASI)
Shionogi & Co., Ltd. Unsponsored ADR (ALCD.)
Shionogi & Co., Ltd. Unsponsored ADR (OMNN)
Shionogi & Co., Ltd. Unsponsored ADR (CGPI.)
Shionogi & Co., Ltd. Unsponsored ADR (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 824667109
SIC: 8880
Fiscal Year
Fiscal Year End: March
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 10/27/25
Share - Related Items
Shares Outstanding: 1,701.38
Most Recent Split Date: 10.00 (1.50:1)
Beta: 0.20
Market Capitalization: $15,227.34 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 1.71%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.15
Current Fiscal Year EPS Consensus Estimate: $0.73 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 6.05% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 10/27/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 12.26
Trailing 12 Months: 15.26
PEG Ratio: 2.03
Price Ratios
Price/Book: 1.69
Price/Cash Flow: 12.11
Price / Sales: 5.35
EPS Growth
vs. Year Ago Period: 41.18%
vs. Previous Quarter: 14.29%
Sales Growth
vs. Year Ago Period: 10.34%
vs. Previous Quarter: 0.61%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -
12/31/24 - -
Current Ratio
06/30/25 - -
03/31/25 - 6.63
12/31/24 - 7.64
Quick Ratio
06/30/25 - -
03/31/25 - 6.13
12/31/24 - 7.01
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - 45.81
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 5.29
12/31/24 - 5.29
Inventory Turnover
06/30/25 - -
03/31/25 - 0.97
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.01
12/31/24 - 0.01
Debt-to-Capital
06/30/25 - -
03/31/25 - 1.33
12/31/24 - 1.41
 

Powered by Zacks Investment Research ©